Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Puma BiotechnologyPBYI -1.91%54 Price-to-Owner-Earnings is 18.52 as of Aug. 14, 2026, which is 64% above its 10-year median of 11.32. GuruFocus rates PBYI with a GF Score™ of 54/100 and a GF Value™ of $3.61 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 207 Biotechnology companies, Puma Biotechnology ranks better than 57.97% on this metric.
As of today (2026-08-14), Puma Biotechnology's share price is $8.705.
Puma Biotechnology's Owner Earnings per Share (TTM) ended in Jun. 2026 was $0.47. It's Price-to-Owner-Earnings for today is 18.52.
The historical rank and industry rank for Puma Biotechnology's Price-to-Owner-Earnings or its related term are showing as below:
PBYI'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.27 Med: 11.32 Max: 131.67
Current: 18.63
During the past 13 years, the highest Price-to-Owner-Earnings of Puma Biotechnology was 131.67. The lowest was 4.27. And the median was 11.32.
PBYI's Price-to-Owner-Earnings is ranked better than 57.97% of 207
companies
in the Biotechnology industry
Industry Median: 25.54
vs PBYI: 18.63
Puma Biotechnology Price-to-Owner-Earnings Related Terms
Puma Biotechnology Price-to-Owner-Earnings Historical Data
* Premium members only.
The historical data trend for Puma Biotechnology's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBYI vs EVMN, OCGN, EDIT: Price-to-Owner-Earnings Comparison
For the Biotechnology subindustry, Puma Biotechnology's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Puma Biotechnology Price-to-Owner-Earnings vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Puma Biotechnology's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Puma Biotechnology's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Price-to-Owner-Earnings of 18.52 mean?
Puma Biotechnology (PBYI) has a Price-to-Owner-Earnings of 18.52 as of Aug. 14, 2026. Price-to-owner-earnings ratio is the ratio of share price to a company's Buffett owner earnings per share. View historical data on Puma Biotechnology and its competitors. This is 64% above median its historical median of 11.32. Over the past decade, Puma Biotechnology's Price-to-Owner-Earnings has ranged from 4.27 to 131.67. According to the industry distribution chart, Puma Biotechnology ranks #87 out of 207 companies in the Biotechnology industry, placing it in the top 42%.
Is Puma Biotechnology's Price-to-Owner-Earnings too high?
Puma Biotechnology's current Price-to-Owner-Earnings of 18.52 is 64% above median its 10-year median of 11.32. Over the past 10 years, this metric has ranged from a low of 4.27 to a high of 131.67. The Biotechnology industry median Price-to-Owner-Earnings is 25.54. Puma Biotechnology's value of 18.52 is 27.5% below this industry median. Based on the distribution chart, Puma Biotechnology ranks #87 out of 207 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Puma Biotechnology has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's Price-to-Owner-Earnings compare to EVMN and OCGN?
According to the Biotechnology industry distribution chart, Puma Biotechnology ranks #87 out of 207 companies for Price-to-Owner-Earnings. This puts Puma Biotechnology in the upper half of its industry. The industry median Price-to-Owner-Earnings is 25.54. Puma Biotechnology's value of 18.52 is 27.5% below this benchmark. Historically, Puma Biotechnology's own Price-to-Owner-Earnings has ranged from 4.27 to 131.67 over the past decade. While the company's 10-year median is 11.32 vs. the industry median of 25.54, Puma Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Owner-Earnings for a Biotechnology company?
The median Price-to-Owner-Earnings among Biotechnology companies is 25.54, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Owner-Earnings significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Owner-Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Puma Biotechnology's current Price-to-Owner-Earnings of 18.52 is 27.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Owner-Earnings mean?
A high Price-to-Owner-Earnings can signal that a stock is expensive relative to its fundamentals. Price-to-owner-earnings ratio is the ratio of share price to a company's Buffett owner earnings per share. View historical data on Puma Biotechnology and its competitors. For the Biotechnology industry, the median Price-to-Owner-Earnings is 25.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Puma Biotechnology's current Price-to-Owner-Earnings is 18.52, which is 64% above median its own 10-year median of 11.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.61, compared to a current price of $8.71 — trading 141.1% above its estimated fair value. The current Price-to-Owner-Earnings is 18.52, which is 64% above median its 10-year median of 11.32 and 27.5% below the Biotechnology industry median of 25.54. Puma Biotechnology's overall GF Score™ is 54/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Owner-Earnings calculated?
Price-to-Owner-Earnings is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current Price-to-Owner-Earnings is 18.52 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Puma Biotechnology (PBYI) Overvalued in 2026?
Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued.
The current stock price of $8.71 is trading 141.1% above its estimated GF Value™ of $3.61.
GuruFocus considers Puma Biotechnology to be Significantly Overvalued.
Key valuation signals for PBYI:
Price-to-Owner-Earnings: 18.52 (64% above median its 10-year median of 11.32)
GF Value™: $3.61 vs. price of $8.71 (141.1% above fair value)
Industry Position: 27.5% below the Biotechnology median (#87 of 207)
No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
54GF Score
Get the complete analysis for PBYI
Price-to-Owner-Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBYI has been successfully added to your 
